Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
Novartis shareholders vote in favor of Sandoz spinoff, separation set for early October
Novartis’ Sandoz spinoff is right on track following a shareholder vote in favor of a full separation on Friday.
The generics and biosimilars unit is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
